Shawn Mendes' "Heart of Gold" debuts at No. 7 on two charts in the U.K., just one week after "Why ... [+] Why Why" earned the singer another top 10 on two tallies. RIO DE JANEIRO, BRAZIL ...

In a report released today, Uy Ear from Mizuho Securities maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price target of $9.00. The company’s shares closed ...

Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...

The cause of death was not immediately known, but the former goalie, hockey executive and broadcaster battled mental health issues. “Simmer,” as he was affectionately called, was just 56.

Sage Therapeutics stock opened at $7.44 on Friday. The business’s 50-day simple moving average is $5.64 and its 200 day simple moving average is $7.53. The stock has a market cap of $455.13 ...

"That was a nice early birthday present," Statesville resident Shawn Snook told the NC Education Lottery. Snook bought his $3 ticket for the Dec. 17 drawing using Online Play. His ticket matched ...

The FBI on Tuesday said an email that appeared to have been sent from the Las Vegas Cybertruck explosion subject Matthew Livelsberger to prominent podcaster Shawn Ryan was indeed confirmed to have ...

Sage Therapeutics (SAGE) announced that its board of directors has initiated a process to explore strategic alternatives for the company. The board intends to evaluate a broad range of ...

Vanessa Leroy / Bloomberg via Getty Images Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own.

Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Sage's board will look at a range of ...

Sage Therapeutics (SAGE) said Biogen (BIIB) has made an unsolicited offer to acquire the rest of SAGE shares. Biogen currently owns a 10.2% stake in Sage Therapeutics; SAGE board members will ...